University research labs across the United States are facing unprecedented uncertainty as the National Institutes of Health (NIH), the nation's primary funder of biomedical research, has obligated just 15 percent of its extramural research funding halfway through fiscal year 2026. This sluggish pace, revealed in recent analyses by the Association of American Medical Colleges (AAMC) and the Association of American Universities (AAU), equates to approximately $5.8 billion out of an estimated $38 billion available for grants and contracts. By contrast, in the prior full fiscal year under the previous administration, the NIH had committed nearly $9 billion by the same midpoint.

The delay stems from a perfect storm of factors, including a prolonged government shutdown from October 1 to November 12, 2025, which halted all new obligations for the first seven weeks of the fiscal year. Compounding this, staffing shortages at the NIH—exacerbated by recent layoffs—have slowed grant reviews and awards. As of late February 2026, the agency had issued 66 percent fewer grant awards than the average for the same period in fiscal years 2021 through 2024, with the dollar value of those awards down by 54 percent.

Shift to Multi-Year Funding Reshapes Grant Landscape

A major contributor to the slowdown is the NIH's pivot to a multi-year funding model, where the full amount for multi-year grants is obligated upfront in the first year. This 'mortgage-free' approach eliminates future-year commitments but drastically reduces the number of new awards available annually. In fiscal year 2025, forward funding for new grants jumped from 5-15 percent to about 40 percent, leading to 5,564 fewer grants overall and success rates plummeting to 17 percent—the lowest in nearly 30 years.

For universities reliant on NIH support, this means fewer opportunities to launch innovative projects. Research-intensive institutions like Johns Hopkins University, a perennial top recipient, have reported substantial shortfalls in both the number and value of awards compared to historical averages. Lab directors at such campuses are scrambling to bridge gaps, often dipping into institutional funds or delaying hires.

Early-Career Researchers Bear the Brunt

Junior faculty and postdoctoral researchers, classified as early-stage investigators (ESIs), are disproportionately affected. Success rates for ESI R01-equivalent grants dropped to 18.5 percent in fiscal year 2025 from 29.8 percent two years earlier. A national survey of nearly 1,000 NIH-funded researchers found that 65 percent with delayed or cut grants had not seen full restoration by year's end, prompting lab closures and layoffs.

At the University of California, San Francisco (UCSF), one of the NIH's largest grantees, funding disruptions have led to stalled experiments and uncertain futures for young scientists. Stanford University and Harvard University have imposed hiring freezes on medical researchers, citing the volatility. 'Every university I know has either reduced force or frozen hiring,' noted Lizbet Boroughs of the AAU.

PhD programs in life sciences are scaling back admissions, with some departments warning incoming students that stipends may not materialize. This threatens the biomedical research pipeline, as trainees gain fewer hands-on opportunities and risk abandoning academia altogether.

Real-World Case Studies from Campuses Nationwide

Ohio State University provides a stark example: earlier disruptions in 2025 terminated dozens of studies, and ongoing delays have forced postdoc layoffs and project pauses. At Johns Hopkins, analysts using NIH RePORTER data highlighted a 'dramatic slowdown,' with ripple effects on clinical trials and basic science.

Even states are intervening. Massachusetts and New York have launched billion-dollar research funds to stabilize labs amid federal uncertainty. These initiatives underscore how NIH delays strain university budgets, diverting resources from teaching and infrastructure to propping up research operations.

Clinical research feels the pinch acutely. The National Cancer Institute (NCI), with its $7.3 billion budget, is extending trial networks on one-year bridges, risking lapses if funds don't flow soon. Opioid addiction programs and rare disease studies face similar fates, potentially returning unspent dollars to the Treasury.

Stakeholder Perspectives: Alarm and Calls for Action

The AAMC warns that 'predictable, sustainable funding is critical for scientific progress.' Deborah Altenburg of the Association of Public and Land-grant Universities (APLU) emphasized, 'Institutions can't float labs indefinitely without timely approvals.'

NIH Director Jay Bhattacharya has pushed back, assuring Congress the full $47.2 billion appropriation will be spent. 'Don't pay attention to the hype—grants are going out the door,' he stated, touting reforms like unified funding strategies and prioritizing 'rigorous science' over outdated ideas. He attributes delays partly to the shutdown and promises accelerated reviews with more staff.

Critics, however, point to centralized NOFO approvals—now 16 steps at NCI—and fewer solicitations (14 posted in 2026 vs. 756 in 2024) as stifling investigator-initiated research. Political appointee oversight raises merit-review concerns.

Broader Implications for Higher Education

US universities, hosting 80 percent of NIH-funded research, face cascading effects. Biomedical departments see eroded competitiveness, with faculty time shifted from benches to grant-writing marathons. Innovation slows as 'shots on goal' dwindle, potentially delaying cures for cancer, Alzheimer's, and emerging threats.

For more details on tracking NIH awards, visit the AAMC's real-time dashboard, updated biweekly.

Explore raw data via the NIH's RePORTER tool, which reveals FY2026 trends.

Navigating the Uncertainty: Strategies for Researchers

• Diversify funding sources: Pursue NSF, private foundations like HHMI, or state programs.
• Leverage institutional bridges: Many campuses offer short-term lab support; communicate early.
• Collaborate strategically: Join consortia to share costs and boost grant success.
• Advocate: Engage AAU/APLU for policy change; track AAU's analyses here.
• Prepare for multi-year shifts: Budget conservatively, focusing on high-impact, flexible projects.

Early-career faculty should prioritize ESI-designated opportunities and mentorship networks.

Photo by Fotos on Unsplash

Future Outlook and Path Forward

With six months left in FY2026, the NIH faces a spending sprint reminiscent of last year's end-game rush. Bhattacharya pledges normalization, but skeptics fear fewer new grants overall. Congress may scrutinize in hearings, potentially mandating staffing boosts or streamlined processes.

For higher education, resilience lies in hybrid funding models and policy advocacy. As universities adapt, the crisis highlights NIH's pivotal role in sustaining America's research supremacy. Timely reforms could turn delays into a catalyst for efficient, impactful science.